Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.35 |
| ▸ | HTR2B | P41595 | 4/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33525767 | 0.83 | NOS3 (0.36) | PARP1NOS3NOS1ELANEKMT2A | |
| SCHEMBL4656934 | 0.81 | PARP2 (0.42) | PARP1PARP2L3MBTL1NOS3NOS1 | |
| SCHEMBL20525292 | 0.81 | PARP1 (0.43) | PARP1FPR2HTR2CHTR2BPARP2 | |
| SCHEMBL4655667 | 0.80 | PARP2 (0.41) | PARP1PARP2L3MBTL1CYP2D6 | |
| SCHEMBL4654650 | 0.80 | PARP2 (0.43) | PARP1PARP2L3MBTL1CYP2D6 | |
| SCHEMBL5376146 | 0.79 | PARP2 (0.45) | PARP1PARP2PARP3CYP2D6 | |
| SCHEMBL5376108 | 0.79 | PARP1 (0.43) | PARP1 | |
| SCHEMBL4656278 | 0.78 | SMN1; SMN2 (0.49) | PARP1PARP2 | |
| SCHEMBL4654387 | 0.78 | PARP1 (0.44) | PARP1PARP2KMT2ACYP2D6 | |
| SCHEMBL23336233 | 0.77 | FPR2 (0.39) | PARP1FPR2HTR2CHTR2BNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | HAN WEI | 2007-05-03 | — | — | US | disclosed |
| US-7169795-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | TFPI, F12, F5 | PARP1 1406/4885FPR2 3990/4885HTR2C 4343/4885 |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, F12, F5 | PARP1 1406/4885FPR2 3990/4885HTR2C 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.